Carregant...
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating...
Guardat en:
| Publicat a: | Cells |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8157002/ https://ncbi.nlm.nih.gov/pubmed/34067729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10051225 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|